Rapamycin and rapalogs even though came to clinical use, suffered various drawbacks like incomplete inhibition of mTORC1 target 4E-BP1, a negative feedback inhibition that lead to increased Akt activation thereby allowing cancer survival and no significant effect on mTORC2 functions19. Here, EIF4EBP1 is linked to cancer.